Formerly, Bernard served as the Director of the National TB Research Programme of the MRC. His experience is in drug and vaccine development for TB, and in the refinement of molecular diagnostics procedures for drug resistant tuberculosis.
He has also been instrumental in the formulation and development of fixed-dose combinations of anti-tuberculosis agents and in setting up performance criteria for these. Bernard Fourie has contributed to establishing the capacity for Phase II early bactericidal activity studies in South Africa, and have been involved in clinical evaluation of several existing and new drugs against TB.
Recently, he made relevant contributions to the field of pulmonary delivery of vaccines and drugs. Current research contributions are mainly in rapid molecular diagnostics for TB, and in developing inhaled clofazimine as a new dosage form for application in drug resistant tuberculosis.
He acts as international consultant on interventions for TB and HIV for the World Health Organization, UNITAID, the United Nations Industrial Development Organization and the German Technical Cooperation (GIZ).